Clarithromycin pharmacokinetics in healthy young and elderly volunteers
- PMID: 1474166
- DOI: 10.1002/j.1552-4604.1992.tb03809.x
Clarithromycin pharmacokinetics in healthy young and elderly volunteers
Abstract
The pharmacokinetics of clarithromycin and its active 14(R)-hydroxy metabolite were assessed in 12 healthy young and 12 healthy elderly volunteers after oral administration of a multiple dose regimen of oral clarithromycin (500 mg every 12 hours for 5 doses). Plasma and urine clarithromycin and 14(R)-hydroxyclarithromycin concentrations were determined using high-performance liquid chromatography. The elderly subjects exhibited significantly elevated clarithromycin peak (Cmax) and trough (Cmin) plasma concentrations and area under the plasma concentration-time curve (AUC) compared with young subjects. In addition, the elderly group exhibited a significantly reduced apparent total body clearance (300 +/- 97 versus 476 +/- 112 mL/min, respectively) and renal clearance (CLR) (84 +/- 31 versus 168 +/- 35 mL/min, respectively). Similar results were noted for the 14(R)-hydroxy metabolite, with significantly elevated Cmax, Cmin, and AUC and reduced CLR in the elderly compared with the young group. Because the differences in parent and metabolite pharmacokinetic parameters were small and the increase in circulating drug concentrations was well tolerated (no increase in incidence or severity of adverse events), adjustments in clarithromycin dosing regimens may not be necessary solely on the basis of age.
Similar articles
-
Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.J Clin Pharmacol. 1993 Aug;33(8):719-26. doi: 10.1002/j.1552-4604.1993.tb05613.x. J Clin Pharmacol. 1993. PMID: 8408732
-
Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.J Clin Pharmacol. 1993 May;33(5):480-5. doi: 10.1002/j.1552-4604.1993.tb04692.x. J Clin Pharmacol. 1993. PMID: 8331208
-
Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.Antimicrob Agents Chemother. 1992 Nov;36(11):2447-53. doi: 10.1128/AAC.36.11.2447. Antimicrob Agents Chemother. 1992. PMID: 1489187 Free PMC article. Clinical Trial.
-
Clarithromycin clinical pharmacokinetics.Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003. Clin Pharmacokinet. 1993. PMID: 8222460 Review.
-
Clinical pharmacokinetics of mizolastine.Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.
Cited by
-
Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes.PLoS Negl Trop Dis. 2015 Dec 2;9(12):e0004253. doi: 10.1371/journal.pntd.0004253. eCollection 2015 Dec. PLoS Negl Trop Dis. 2015. PMID: 26630648 Free PMC article.
-
Interaction between midazolam and clarithromycin in the elderly.Br J Clin Pharmacol. 2008 Jan;65(1):98-109. doi: 10.1111/j.1365-2125.2007.02970.x. Epub 2007 Jul 17. Br J Clin Pharmacol. 2008. PMID: 17635500 Free PMC article. Clinical Trial.
-
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.Antimicrob Agents Chemother. 2003 Feb;47(2):739-46. doi: 10.1128/AAC.47.2.739-746.2003. Antimicrob Agents Chemother. 2003. PMID: 12543686 Free PMC article.
-
Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.Antimicrob Agents Chemother. 1996 Jul;40(7):1617-22. doi: 10.1128/AAC.40.7.1617. Antimicrob Agents Chemother. 1996. PMID: 8807050 Free PMC article.
-
Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.Drugs. 1993 Aug;46(2):289-312. doi: 10.2165/00003495-199346020-00007. Drugs. 1993. PMID: 7691518 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources